---
title: "Replimune 公司股价翻倍，此前美国 FDA 接受其皮肤癌药物潜在获批的补充申请，该股最新涨幅达 106.2%。"
description: "Replimune 公司股价翻倍，此前美国 FDA 接受其皮肤癌药物潜在获批的补充申请，该股最新涨幅达 106.2%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261903770.md"
published_at: "2025-10-20T13:41:23.000Z"
---

# Replimune 公司股价翻倍，此前美国 FDA 接受其皮肤癌药物潜在获批的补充申请，该股最新涨幅达 106.2%。

Replimune 公司股价翻倍，此前美国 FDA 接受其皮肤癌药物潜在获批的补充申请，该股最新涨幅达 106.2%。

### Related Stocks

- [REPL.US - Replimune](https://longbridge.com/zh-CN/quote/REPL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/zh-CN/news/276017486.md) |
| 09:00 ETDrug Allergy Labels Rarely Evaluated for Children with Primary Immunodeficiencies | Drug allergy labels (DAL) are prevalent but often unassessed in children with primary immunodeficiencies, potentially le | [Link](https://longbridge.com/zh-CN/news/275912085.md) |
| Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins | Nuclera and leadXpro have announced a partnership to enhance structure-based drug design for complex membrane proteins.  | [Link](https://longbridge.com/zh-CN/news/276109364.md) |
| 06:07 ETMolecule Found to Drive Skin Cancer Growth and Evade Immune Detection | A study led by NYU Langone Health reveals that the transcription factor HOXD13 drives skin cancer growth and helps tumor | [Link](https://longbridge.com/zh-CN/news/275593928.md) |
| IDT Australia Reports Operational Improvements with New Leadership Team and Realignment Strategy | IDT Australia reported operational improvements under a new leadership team and realignment strategy, with a 20.3% incre | [Link](https://longbridge.com/zh-CN/news/276194130.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。